David Z Chang

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. pmc Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
    David Z Chang
    Departments of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    J Hematol Oncol 2:18. 2009
  2. pmc Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma
    David Z Chang
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:7015-23. 2011
  3. pmc Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression
    David Z Chang
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Hematol Oncol 5:15. 2012
  4. doi request reprint Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
  5. pmc Effects of base excision repair gene polymorphisms on pancreatic cancer survival
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1402, USA
    Int J Cancer 120:1748-54. 2007
  6. ncbi request reprint Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    Dario Ribero
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2761-7. 2007
  7. doi request reprint Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:2000-5. 2008
  8. pmc Ras activity levels control the development of pancreatic diseases
    Baoan Ji
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 137:1072-82, 1082.e1-6. 2009
  9. ncbi request reprint Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites
    Satoshi Ishiyama
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Oncol 30:889-98. 2007
  10. ncbi request reprint Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models
    Kuichun Zhu
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Vaccine 25:7955-61. 2007

Collaborators

Detail Information

Publications25

  1. pmc Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
    David Z Chang
    Departments of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    J Hematol Oncol 2:18. 2009
    ..It should now become a standard practice that any patients being considered for EGFR targeted therapies have their tumors tested for KRAS status and only those with wild-type KRAS being offered such therapies...
  2. pmc Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma
    David Z Chang
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:7015-23. 2011
    ..Inflammatory cells, particularly mast cells, have been shown to play key roles in some cancers. We carried out this study to test the hypothesis that mast cells in the tumor microenvironment are essential for PDAC tumorigenesis...
  3. pmc Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression
    David Z Chang
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Hematol Oncol 5:15. 2012
    ..In this retrospective study, we determined whether aberrant CDC20 expression can be used as a biomarker in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis and whether its expression reflects clinical progression...
  4. doi request reprint Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  5. pmc Effects of base excision repair gene polymorphisms on pancreatic cancer survival
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1402, USA
    Int J Cancer 120:1748-54. 2007
    ..These observations need to be confirmed in a larger study of homogenous patient population...
  6. ncbi request reprint Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    Dario Ribero
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2761-7. 2007
    ..The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology...
  7. doi request reprint Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:2000-5. 2008
    ..It is unclear to what extent aspects of this "Critical Path Initiative" have been adopted in trial designs in metastatic colorectal cancer...
  8. pmc Ras activity levels control the development of pancreatic diseases
    Baoan Ji
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 137:1072-82, 1082.e1-6. 2009
    ..However, we hypothesized that acinar cells would develop PDAC in the presence of Ras activity levels mimicking those of human tumor cells...
  9. ncbi request reprint Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites
    Satoshi Ishiyama
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Oncol 30:889-98. 2007
    ..Immunotherapy with tumor antigens from Notch and Numb should be important for treatment of cancer patients...
  10. ncbi request reprint Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models
    Kuichun Zhu
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Vaccine 25:7955-61. 2007
    ..We conclude that survivin DNA vaccine generated specific antitumor effects with increased lymphocyte infiltration at the tumor sites...
  11. pmc Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer
    Li Jiao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:840-8. 2007
    ..The authors hypothesized that genetic variants of glutathione S-transferase (GST) affect detoxification of carcinogens and anticancer agents in the human pancreas and, thus, the risk and survival of pancreatic cancer...
  12. ncbi request reprint Mitogen stimulation activates different signaling pathways in early- and late-divided T cells as revealed by cDNA microarray analysis
    Yufeng Li
    Graduate School of Biomedical Science, UT Health Science Center at Houston, Houston, TX 77030, USA
    Int J Mol Med 18:1127-39. 2006
    ..Because most tumors are infiltrated by lymphocytes, our studies indicate a novel approach to identify 'systemic biological responses' of T cells, which could determine the design, and optimization of effective tumor vaccines...
  13. ncbi request reprint Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells
    Naotake Tsuda
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:8378-87. 2007
    ..Elucidation of the composition of ISMMC and identification of adducts formed by Taxol should be important for developing molecular cancer vaccines...
  14. pmc Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity
    Zhiliang Jia
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 70:1111-9. 2010
    ....
  15. pmc Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals
    Chantale Bernatchez
    Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, United States
    Vaccine 29:3021-30. 2011
    ..Thus, vaccinating with both the 10-mer and 9-mer peptides would be required to immunize a maximum number of individuals in the HLA-A0201(+) population and could lead to more consistent T-cell responses against this region of Survivin...
  16. ncbi request reprint HLA-A0201 positive pancreatic cell lines: new findings and discrepancies
    Kuichun Zhu
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Immunol Immunother 56:719-24. 2007
    ..Our findings were verified with two different sequence-based typing methods, antibody staining followed by flow cytometry analysis, and functional analysis using an HLA-A0201-restricted peptide-specific T cell response...
  17. ncbi request reprint Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival
    Yun Shin Chun
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 11:1498-504; discussion 1504-5. 2007
    ..The aim of this study was to compare the outcome of patients with CLM treated with preoperative chemotherapy followed by one- or two-stage hepatectomy...
  18. doi request reprint Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness
    Seth Politano
    University of Texas Health Science Center, Houston, TX, USA
    Clin Colorectal Cancer 7:55-9. 2008
    ..However, it is unclear which patient, disease, and treatment characteristics are associated with the utilization of a second-line regimen...
  19. pmc Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4311-8. 2008
    ..Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors...
  20. ncbi request reprint Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells
    Naotake Tsuda
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Clin Cancer Res 12:6557-64. 2006
    ..Inhibiting cancer cell proliferation by targeting the Gli-1 effector pathway is difficult to achieve by chemotherapeutic agents or short interfering RNA...
  21. pmc Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer Res 66:3323-30. 2006
    ..These observations suggest that polymorphisms of genes involved in the repair of DNA double-strand breaks significantly affect the clinical outcome of patients with pancreatic cancer...
  22. ncbi request reprint Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX
    David Z Chang
    M D Anderson Cancer Center, University of Texas, TX, USA
    Clin Adv Hematol Oncol 3:400-4. 2005
  23. ncbi request reprint The current status of vaccine development in colorectal cancer
    David Z Chang
    GI Medical Oncology and Immunology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 5:109-11, 136. 2007
  24. doi request reprint Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy
    Prakash Thapa
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77054, USA
    Vaccine 27:3484-8. 2009
    ..Hence, nanoparticle formulated alpha-galactosylceramide is an attractive immunomodulator for immunotherapy and vaccine development. Future studies will be focused on its application as adjuvant for protein and/or peptide antigens...